Natural Health Trends Corp. — 2022 Form 10-K Summary
Business context and reporting period
The filing covers the fiscal year ended December 31, 2022, compared with fiscal 2021; it does not provide standalone fourth-quarter results. Natural Health Trends sells wellness, personal care and lifestyle products through e-commerce and an independent-member direct-selling network. Its business is highly concentrated in Hong Kong: 78.2% of 2022 net sales were recorded there, and substantially all Hong Kong sales were delivered to members in China. The company reported 38,660 active members at year-end, down from 45,760.
Key financial results
| Metric | 2022 | 2021 |
|---|---|---|
| Net sales | $49.1 million | $60.0 million |
| Gross profit / margin | $36.5 million / 74.2% | $45.0 million / 75.0% |
| Operating income (loss) | ($0.27 million) / (0.6%) | $1.57 million / 2.6% |
| Net income | $0.31 million | $1.09 million |
| Diluted EPS | $0.03 | $0.09 |
| Operating cash flow | ($4.85 million) | $1.02 million |
- Revenue fell 18% year over year. Hong Kong sales declined 18% to $38.4 million; sales outside Hong Kong declined 20%.
- Gross margin decreased 0.8 percentage points; management cited higher logistics costs, excluding the effect of lower administrative-fee revenue. Commissions were 42.2% of sales versus 42.6%. SG&A declined 10% in dollars to $16.0 million but rose to 32.6% of sales from 29.8% as revenue fell faster than costs.
- Other income, net, was $0.87 million versus a $0.06 million expense in 2021. The filing does not clearly explain the full year-over-year change; it reports foreign-exchange losses of $0.27 million in 2022.
- Year-end cash and cash equivalents were $69.7 million, including $56.8 million of available-for-sale investments classified as cash equivalents; cash declined from $83.8 million. Working capital was $57.1 million and the current ratio was 3.79.
- No conventional borrowings are reported in the supplied financial statements. Operating lease liabilities totaled $4.12 million. Income taxes payable included a $12.1 million repatriation-tax liability, of which $9.1 million was noncurrent. About $4.2 million of cash was held in China subject to foreign-currency controls.
- Investing cash outflow was $0.14 million; financing cash outflow was $9.14 million, entirely quarterly dividends of $0.20 per share. The board declared another $0.20 quarterly dividend in February 2023. The filing says continued dividends are expected for the foreseeable future, subject to board discretion and financial conditions.
Material changes, outlook and risks
Management attributed the sales decline and negative operating cash flow primarily to COVID-19 outbreaks and government restrictions in China and Hong Kong, which limited member interaction and caused logistics and distribution difficulties early in 2022. Restrictions were substantially relaxed late in 2022, but management said the duration and business impact were uncertain. It anticipated near-term financial performance could remain adversely affected; no quantified earnings or revenue guidance was provided.
- Active membership declined 16% during 2022. Management identifies member losses as a significant contributor to falling sales.
- China regulatory exposure remains material: the company has no Chinese direct-selling license, and it cannot predict if or when one may be obtained. Its Hong Kong sales concentration creates substantial geographic and operational risk.
- Three products—Premium Noni Juice, Enhanced Essential Probiotics and Triotein—each accounted for at least 10% of revenue and each depended on a single supplier.
- Other disclosed risks include direct-selling and product-claim regulation, supply-chain interruptions, geopolitical and trade tensions, foreign-exchange movements, product liability, and cybersecurity and data-privacy risks. The company said it does not maintain a comprehensive product-liability insurance program.
- The company reported no legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end. The auditor issued an unmodified opinion on the financial statements; it did not express an opinion on internal control effectiveness.
Most important facts for investors to verify
- Whether sales, active-member counts and logistics conditions in China and Hong Kong stabilize after the late-2022 easing of restrictions.
- Whether operating cash flow improves enough to support ongoing dividends and operations; 2022 operating cash flow was negative while dividends totaled $9.1 million.
- The company’s regulatory status in China, including any new examinations, restrictions or progress toward a direct-selling license.
- Whether reliance on three major single-supplier products and the concentrated Hong Kong/China sales base changes.
- The nature and sustainability of the 2022 other-income benefit and the accessibility of cash subject to foreign-exchange controls.